A Randomised, Double-blind, Placebo-Controlled, Two-way Cross-over, Single Centre Study in Healthy Subjects to Assess the Effect of Oral Dosing of AZD5069 on Neutrophil Number and Function in Peripheral Blood and the Ability to Recruit Neutrophils Into the Circulation After Exercise and Subcutaneous.
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2015
At a glance
- Drugs AZD 5069 (Primary)
- Indications Bronchiectasis; Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 09 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 31 Jul 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 17 Jan 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.